Results 21 to 30 of about 25,252 (242)

Caspofungin MIC Distribution amongst Commonly Isolated Candida Species in a Tertiary Care Centre - An Indian Experience [PDF]

Journal of Clinical and Diagnostic Research, 2016
Introduction: Emergence of Candida species resistant to Amphotericin B and triazole has led to use of echinocandins, mostly caspofungin in the management of invasive candidiasis.
Shashir Wanjare, Rajarshi Gupta, Preeti Mehta   +2 more
doaj   +1 more source

Assessment of Caspofungin use at a Tertiary Teaching Hospital and compliance with IDSA guidelines and FDA labelings

Saudi Pharmaceutical Journal, 2022
Objective: The aim of this study is to evaluate the utilization pattern of Caspofungin in an academic tertiary care hospital in Riyadh, Saudi Arabia. Methods: This is a retrospective study, conducted at King Saud University Medical City, Riyadh, Saudi ...
Abrar F. Alshehri, Thamer A. Almangour, Abdullah A. Alhifany, Abdulaziz Alhossan   +3 more
doaj   +1 more source

Caspofungin [PDF]

Clinical Infectious Diseases, 2003
Caspofungin, the first inhibitor of fungal beta-1,3 glucan synthesis to receive approval by the United States Food and Drug Administration, is effective for the treatment of mucosal and invasive candidiasis and invasive aspergillosis. It is also active in vitro and in animal models against a number of other filamentous and dimorphic endemic fungi and ...
Louis D. Saravolatz, Stanley C. Deresinski, David A. Stevens   +2 more
openaire   +2 more sources

Hsp90 governs dispersion and drug resistance of fungal biofilms [PDF]

, 2011
Fungal biofilms are a major cause of human mortality and are recalcitrant to most treatments due to intrinsic drug resistance. These complex communities of multiple cell types form on indwelling medical devices and their eradication often requires ...
A Lupetti, A Viudes, C d'Enfert, CA Kumamoto, CJ Nobile, CJ Nobile, D Andes, D Shahinas, David Andes, E Mowat, EM Kojic, ET Burt, G Ramage, G Ramage, G Ramage, G Ramage, G Ramage, Gordon Ramage, J McCourtie, J Nett, J Trepel, JB Anderson, JC Young, JE Nett, Jeniel Nett, Jose L. Lopez-Ribot, JR Blankenship, JS Finkel, L Ostrosky-Zeichner, LE Cowen, LE Cowen, LE Cowen, LE Cowen, LE Cowen, Leah E. Cowen, LH Pearl, LS Wilson, M Taipale, MA Pfaller, MA Pfaller, MJ Seidler, ML Richard, MM McNeil, Nicole Robbins, P Perumal, P Uppuluri, P Uppuluri, P Uppuluri, P Uppuluri, P Uppuluri, PK Mukherjee, Priya Uppuluri, R Pallavi, Ranjith Rajendran, Robin Charles May, RS Shapiro, RS Shapiro, S Garcia-Sanchez, S Park, S Perea, SD Singh, SJ Lin, SL LaFayette, SM Noble, SV Balashov, SZ Usmani, TE Zaoutis, Y Kaneko, YS Kim, Z Odabasi   +69 more
core   +22 more sources

Therapeutic potential of caspofungin combined with trimethoprim-sulfamethoxazole for pneumocystis pneumonia: a pilot study in mice. [PDF]

PLoS ONE, 2013
Pneumocystis pneumonia (PcP) is a major cause of mortality and morbidity in immunocompromised patients. There are limited alternative therapeutic choices to trimethoprim-sulfamethoxazole (TMP-SMX) which is the standard first line therapy/prophylaxis for ...
Maria Luísa Lobo, Francisco Esteves, Bruno de Sousa, Fernando Cardoso, Melanie T Cushion, Francisco Antunes, Olga Matos   +6 more
doaj   +1 more source

Membrane Integrity Contributes to Resistance of Cryptococcus neoformans to the Cell Wall Inhibitor Caspofungin

mSphere, 2022
The fungal pathogen Cryptococcus neoformans causes up to 278 000 infections each year globally, resulting in up to 180,000 deaths annually, mostly impacting immunocompromised people. Therapeutic options for C.
Brenda Moreira-Walsh, Abigail Ragsdale, Woei Lam, Rajendra Upadhya, Evan Xu, Jennifer K. Lodge, Maureen J. Donlin   +6 more
doaj   +1 more source

Cost-utility analysis of caspofungin and fluconazole for primary treatment of invasive candidiasis and candidemia in Ethiopia

BMC Health Services Research, 2022
Background Invasive candidiasis and/or candidemia (IC/C) is a common fungal infection leading to significant health and economic losses worldwide. Caspofungin was shown to be more effective than fluconazole in treating inpatients with IC/C. However, cost-
Gebremedhin Beedemariam Gebretekle, Atalay Mulu Fentie, Girma Tekle Gebremariam, Eskinder Eshetu Ali, Daniel Asfaw Erku, Tinsae Alemayehu, Workeabeba Abebe, Beate Sander   +7 more
doaj   +1 more source

Roles of Candida albicans Mig1 and Mig2 in glucose repression, pathogenicity traits, and SNF1 essentiality. [PDF]

, 2020
Metabolic adaptation is linked to the ability of the opportunistic pathogen Candida albicans to colonize and cause infection in diverse host tissues. One way that C.
Filler, Scott G, Huang, Manning Y, Lagree, Katherine, May, Gemma, McManus, C Joel, Mitchell, Aaron P, Solis, Norma V, Woolford, Carol A   +7 more
core   +3 more sources

Phosphoproteomics of Aspergillus fumigatus Exposed to the Antifungal Drug Caspofungin

mSphere, 2020
Aspergillus fumigatus is an opportunistic and allergenic pathogenic fungus, responsible for fungal infections in humans. A. fumigatus infections are usually treated with polyenes, azoles, or echinocandins.
Eliciane Cevolani Mattos, Giuseppe Palmisano, Gustavo H. Goldman   +2 more
doaj   +1 more source

Development of Antifungal Peptides against Cryptococcus neoformans; Leveraging Knowledge about the cdc50Δ Mutant Susceptibility for Lead Compound Development

Microbiology Spectrum, 2022
Cryptococcus neoformans is a major fungal pathogen that often causes life-threatening meningitis in immunocompromised populations. This yeast pathogen is highly resistant to the echinocandin drug caspofungin.
Robert J. Tancer, Yina Wang, Siddhi Pawar, Chaoyang Xue, Gregory R. Wiedman   +4 more
doaj   +1 more source